| Name | Title | Contact Details |
|---|
Verinata Health is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oxyband Technologies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We were founded in 2006 as GO3ETA, Inc., but do business as the Global Organization for EPA and DHA Omega-3s (GOED). The roots of GOED go back to 2000 when the industry collaborated to petition the US Food and Drug Administration to establish a heart disease risk reduction claim for omega-3s. The companies involved later formalized the relationship by forming the Omega-3 Working Group at the Council for Responsible Nutrition and collaborating again to develop what is now known as the GOED Voluntary Monograph. In 2006, when the Working Group was dissolved, twelve of the companies banded together to found GOED with a strong mandate to grow our membership to represent all sections of the EPA and DHA market.
Trevena is a publicly traded clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. We have three programs in clinical development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently in phase 2 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in phase 1 testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.
Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers.